I treat clinical AI approval as approval of a specific use - not just a model. Before launch, I define the task, assign an owner, trace patient data, and test whether the tool is safe for the patients and clinicians who will use it.
My approach covers 7 lifecycle gates, from intake through reassessment or retirement:
- Assign risk and responsibility: Register each use, set its risk tier, and separate clinical approval from privacy, security, and regulatory reviews.
- Test before use: Check local results, patient-group differences, workflow fit, and applicable FDA, health IT, and HIPAA requirements.
- Keep people in control: Label AI outputs, require meaningful clinician review, and test a non-AI fallback.
- Track and act: Monitor errors, patient harm, data exposure, and model changes. This proactive monitoring helps in taking the risk out of healthcare delivery. Set clear rules for restricting, stopping, restarting, or retiring the tool.
<u>I start with one bounded pilot and require a new approval before expansion.</u> Version-linked records make each decision, change, and response traceable.
Clinical AI Risk Management: 7 Lifecycle Gates
From Deployment to Oversight: Strengthening AI Risk Management and Patient Safety in Health Care
sbb-itb-535baee
AI Intake, Risk Tiers, and Governance Roles
Once a use case is mapped, intake assigns each AI tool a record, a risk tier, and an owner before it enters care.
Create one authoritative inventory record for each AI use case under the AI governance function or enterprise risk office before it reaches clinicians, patients, or EHR workflows. This applies to internal models, supplier-hosted tools, embedded features, and pilots.
Require registration before procurement, contracting, development, pilot use, or production activation. Link embedded features to application and supplier records, and review updates before activating new AI functionality.
Intake Requirements and Risk Tiers
Use one intake form to record:
- Supplier or development team; product, model, version, and release date; sponsor and implementation owner.
- Intended and prohibited uses; users, care settings, and patient populations; training and validation data.
- Input sources; PHI flow, hosting, retention, and secondary use; integrations.
- Outputs and resulting actions; human review and override authority.
- FDA clearance/approval status, if applicable; limitations and performance by subgroup; update and notification obligations.
Ask for supporting evidence, not just supplier assurances. Missing evidence is an open risk item - not approval.
Classify the clinical consequence, not the product label. Assess what could happen if an output is wrong, missing, delayed, biased, or misunderstood. Any use that influences diagnosis or treatment belongs in Tier 3 or higher. These tiers are illustrative internal categories, not FDA classifications or substitutes for legal requirements.
| Internal tier | Use case | Reviewers | Validation | Approval authority | Monitoring | Escalation triggers |
|---|---|---|---|---|---|---|
| 1: Low clinical impact | Nonclinical operations with human correction | Business owner, privacy, security, IT | Functional, data-quality, access, and user acceptance checks | Department leader or delegated approver | Quarterly and after material changes | PHI exposure, record errors, unexpected access, or expansion into clinical use |
| 2: Workflow support | Documentation, coding, prioritization, or communication support with human review | Operations owner, informatics, privacy, security, compliance, users | Retrospective testing, usability review, relevant subgroup analysis, and controlled pilot | AI governance committee or designated service-line authority | Monthly during pilot, then quarterly | Repeated overrides, workflow confusion, privacy events, drift, or out-of-scope use |
| 3: Clinical decision support | Diagnosis, treatment, risk prediction, triage, or medication support | Clinical owner, patient safety, informatics, regulatory/compliance, privacy, security, legal | Local clinical validation, subgroup analysis, human-factors testing, integration testing, and forward-looking pilot monitoring | Executive sponsor following committee recommendation and required domain approvals | Continuous or monthly dashboard review; quarterly reassessment | Unsafe outputs, missed alerts, major bias, drift, integration failure, or loss of human review |
| 4: High-impact or partially autonomous | Autonomous care actions or high-impact use affecting large or vulnerable populations | Relevant governance functions, executive leadership, patient safety, regulatory counsel, independent clinical reviewers | Full validation and change control, safety-case documentation, simulation, forward-looking evaluation, and fallback testing | Executive leadership or authorized enterprise body | Near real time where feasible; frequent formal review | Serious safety events, lost oversight, cyber compromise, material model changes, or fallback failure |
Owners, Responsibilities, and Approval Gates
The executive sponsor provides resources and accepts authorized residual risk. The governance committee sets policy and resolves disputes. The clinical owner defines safe use, patient safety reviews potential harms, and domain reviewers assess privacy, security, and legal or regulatory obligations.
Clinical approval stays separate from privacy, security, regulatory, and procurement sign-offs. The table below defines the evidence required at each gate and who answers for the decision. For committee-owned decisions, name an individual who is accountable.
| Activity and required gate evidence | Accountable decision owner (A) | Responsible contributors (R) | Consulted (C) |
|---|---|---|---|
| Intake: complete record and preliminary tier | Executive sponsor | Intake team, clinical owner, IT/informatics, supplier | Governance and domain reviewers |
| Validation: accepted plan and results | Designated governance lead | Clinical owner, patient safety, data specialists, IT/informatics, supplier | Domain reviewers, frontline users |
| Approval: separate domain sign-offs, conditions, residual risks, renewal date | Executive sponsor | Clinical owner, governance chair, domain reviewers, procurement | Frontline users, supplier |
| Deployment: training, access, monitoring, fallback readiness | Executive sponsor | Clinical owner, IT/informatics, frontline users, supplier | Patient safety and domain reviewers |
| Monitoring: performance and change review | Designated governance lead | Clinical owner, patient safety, data specialists, IT/informatics, frontline users, supplier | Domain reviewers |
| Incidents: escalation, containment, suspension decision | Executive sponsor | Patient safety, clinical owner, IT/informatics, supplier; privacy/security as applicable | Legal/compliance |
| Retirement: disabled access and integrations, data disposition, closure | Executive sponsor | IT/informatics, clinical owner, supplier | Governance, domain reviewers, frontline users |
Routing Assessments With Censinet RiskOps
Censinet RiskOps™ can centralize AI inventory records, third-party and enterprise risk assessments, evidence requests, remediation tracking, and ownership for PHI, clinical applications, devices, and suppliers. Use the intake record to guide validation, workflow design, and go-live approval.
That coordination supports - but does not replace - local validation, regulatory review, human-factors testing, or leadership approval.
Validation and Workflow Design Before Deployment
Clinical Validation and Regulatory Review
After intake assigns risk, validation checks whether the tool can be used safely in the local workflow.
Set testing criteria before testing begins. Define minimum clinical performance, acceptable false-positive and false-negative rates, subgroup disparity limits, alert volume, latency, and availability. Test with local data and assess usability, calibration where relevant, and clinical utility - not just accuracy. Include missing, delayed, incorrect, and conflicting inputs, and report subgroup sample sizes and uncertainty.
Where appropriate, begin with silent-mode testing. Then move to a limited prospective pilot with defined eligibility, duration, reviewers, and stopping rules.
Check whether FDA oversight applies and whether any authorization covers the planned use. Many AI tools are not regulated devices. If the tool is part of certified health IT and qualifies as a decision-support feature covered by ONC HTI-1, review the applicable transparency and risk-management requirements. Obtain clear documentation on intended use, validation, fairness, limitations, and maintenance. Keep validation results, the regulatory rationale, pilot findings, and the approved configuration in the deployment dossier.[6][7][8][9]
Go/no-go checklist
- Evidence and protection: Local performance, subgroup results, usability, pilot findings, and required privacy, security, contractual, and regulatory reviews meet predefined criteria.
- Readiness: Verification, staffing, training, escalation, downtime, and rollback have been tested.
- Decision: Record the decision-maker, rationale, conditions, and review date. Block deployment for unacceptable patient-safety risk, unexplained material disparities, uncontrolled PHI exposure, unsafe automation, or untested rollback. Any permitted residual risks require documented acceptance, mitigation owners, deadlines, and bounded pilot conditions.
PHI Protection and Cybersecurity Controls
Limit PHI to what the approved task needs. Confirm applicable HIPAA duties and business associate agreements, including subcontractor obligations, breach reporting, retention, deletion, and restrictions on training or model improvement.
Review fourth parties and trace PHI through prompts, uploads, outputs, telemetry, support records, and EHR integrations. Verify least-privilege access, strong authentication, encryption, secure API authentication and rate limits, segmentation, secrets management, patching, and recovery.
Test prompt injection, malicious instructions embedded in retrieved content, cross-tenant leakage, and unauthorized actions. Keep audit logs tamper-evident, protect the PHI they contain, and preserve evidence needed for investigations.[4]
| Risk area | Harm to assess | Reviewers | Controls |
|---|---|---|---|
| Patient safety | Missed diagnosis, unsafe advice, delayed care, automation bias, alert fatigue, inequity, or out-of-scope use | Clinical owner, patient safety, specialty experts, quality, human factors | Use limits, local and subgroup validation, clinician verification, labeling, pilot monitoring, incident reporting, rollback |
| PHI protection | Disclosure, excessive collection, secondary use, excessive retention, or PHI exposure in prompts, outputs, or logs | Privacy, health information management, legal, data governance | Data minimization, access controls, retention and deletion rules, contractual restrictions, logs that protect PHI, training |
| Cybersecurity | Account compromise, prompt injection, exfiltration, insecure APIs, supply-chain compromise, model tampering, or denial of service | CISO, security architecture, third-party risk, incident response, vendor security | Authentication, encryption, segmentation, secure APIs, monitoring, vulnerability management, supplier review, incident response |
| Overlapping harms | A cyberattack alters output, a privacy incident reveals a diagnosis, or a faulty model causes clinical harm with reportable privacy or security impact | Clinical, privacy, security, compliance, enterprise risk | Joint threat and hazard analysis, shared escalation, audit trails, change control, downtime, rollback, accountability |
Clinician Review, EHR Placement, and Go-Live Checks
Once validation is complete, define exactly how clinicians will review, verify, and override AI output.
Place outputs where the responsible clinician reviews them. Label them AI-generated, and clearly separate verified findings and orders from AI drafts or recommendations. Show timestamps, data cutoff, material limitations, and model/version details where practical. Provide the source data and validated uncertainty information needed for independent review.
Clinicians need enough time, information, and authority to reject an output - not just a confirmation button.[5][7][9]
| Checkpoint | Required workflow specification |
|---|---|
| Inputs | Authorized sources, required fields, data recency limits, and safe handling of missing or unreliable data |
| Outputs | AI label, status, timestamp, limitations, and source context |
| Reviewer | Accountable review role and backup coverage |
| Allowed use | Permitted actions and explicitly prohibited automation |
| Verification | Source-data checks, patient assessment, and second review where warranted |
| Records | Reviewer, review time, acceptance, modification or override, required rationale, and resulting action |
| Escalation | Unsafe-output triggers, contact route, response expectations, and backup contact |
| Fallback and escalation | Alert prioritization, duplicate suppression, downtime workflow, rollback, and incident reporting |
Before activation, confirm the validated production configuration and correct interface fields. Complete role-specific training, test rollback and non-AI care procedures, and plan patient communication consistent with policy and law. Obtain clinical-owner sign-off based on pilot evidence and staffing capacity. During initial operation, monitor early performance and escalate material workflow or safety issues for reassessment.
Monitoring, Incident Response, and Retirement
Monitoring Metrics and Reassessment Triggers
After go-live, monitoring becomes part of routine clinical control - not a separate review.
Match review frequency to clinical risk and reliance on the tool. For each metric, define its owner, threshold, numerator, denominator, data source, review window, and minimum sample size. Track clinical performance, calibration where relevant, false positives and negatives, subgroup outcomes, overrides, alert burden, near misses, missing inputs, drift, privacy events, and security incidents.
For high-risk uses, governance may approve daily operational checks, weekly exception reviews, and monthly clinical-performance reviews. Use immediate proxy signals while outcomes are pending. Then compare confirmed outcomes with the validated baseline.[1][4]
| Action level | Trigger | Required response |
|---|---|---|
| Investigate | Performance decline, subgroup gap beyond approved tolerance, increasing overrides, or missing-input failures | Clinical and technical owners review affected cases and identify the cause. |
| Restrict | Problems can be contained within a narrower workflow | Limit use to validated settings, require clinician review, or remove automation. |
| Suspend | Risk of patient harm supported by evidence, unsafe recommendations, serious compromise, or an unverified model version or configuration | Stop use and switch to the approved non-AI workflow. |
Reassess after post-deployment changes. These include model updates, interface or data-pipeline changes, new populations or settings, declining performance, misuse, supplier changes, or material changes in guidelines, workflows, coding, lab methods, or regulation. Record whether each change requires targeted testing, full revalidation, new approval, or suspension.
For regulated software as a medical device, compare the change with the supplier’s authorized change-control process and any applicable FDA submission or predetermined change-control documentation. A single severe event can justify suspension even when average metrics remain acceptable.[11][12][13]
Incident Escalation, Suspension, and Retirement
When a threshold is breached, move immediately from review to containment.
Emergency suspension of unsafe use should not wait for a committee meeting. Switch to a validated non-AI workflow or manual process. Define who can stop use and who handles each part of the response:
- The clinical owner addresses patient safety. The privacy officer leads assessment of unauthorized PHI use or disclosure. The security lead coordinates containment of compromise, while IT disables affected integrations and preserves evidence.
- The supplier provides version history and fixes. Legal and compliance handle reporting duties.
Identify affected patients and time periods, investigate harm, and document corrective actions. Not every AI error is a reportable breach. Assess clinical, privacy, security, and regulatory consequences separately.
Restart requires documented evidence that the failure was contained, the cause was understood or acceptably mitigated, and corrective testing was completed. Affected users must be informed, fallback procedures must remain available, and the accountable clinical governance authority must approve the return to service.[2][10]
Retire the tool only after a validated fallback can handle the clinical task without interruption. Record the effective date and obtain clinical, IT, privacy, security, and supplier sign-off. Remove access, credentials, jobs, alerts, and integrations. Disable automation and verify that no hidden or redundant instance remains active.
Apply retention, deletion, and legal-hold rules to data held by the organization and supplier. Verify that removal does not disrupt result routing, follow-up, or pending tasks.[1][4]
AI Lifecycle Records and Audit Trails
Use the same record set to show who reviewed the tool, what changed, and why each decision was made.
Keep a version-linked decision record. Link each review to its owner, affected setting, decision, and next review date. Audit trails should record role-based access, configuration changes, overrides, failures, and incident actions - not unnecessary PHI.
Apply documented retention rules and limit access to approved clinical, quality, privacy, security, compliance, and audit staff. Preserve enough context to establish who acted, what they saw, and what happened next.[14]
Conclusion: Putting Accountable Clinical AI Use Into Practice
Approve the intended use, not just the model. Define the clinical task, users, patient population, data inputs, and allowed decisions. Accuracy alone isn’t enough if the tool exposes patient data or skips required clinician review.
Implementation Phases, Owners, and Required Records
Make the earlier gates part of a repeatable process. Each gate needs a named owner, an approval point, and a required record. This puts governance into daily clinical care rather than treating it as a separate review layer.
| Phase | Deliverable | Accountable owner | Approval | Required records |
|---|---|---|---|---|
| Governance | Policy and approval limits | Chief Medical Information Officer or designated clinical AI executive | Executive and clinical governance approval | Approved charter and risk criteria |
| Intake | Inventory record and intended-use scope | AI product or service-line owner | Completeness review | Intake record and PHI assessment |
| Risk assignment | Risk tier and named owners | Designated governance lead | Tier and ownership approval | Risk rationale and responsibilities |
| Validation | Validation plan and test results | Clinical owner | Clinical and technical sign-off | Subgroup, usability, and failure-mode results |
| Deployment | Safeguards and fallback procedures | Named workflow owner | Go-live approval | Configuration baseline, approvals, and rollback plan |
| Monitoring | Dashboard and response plan | Named workflow owner | Post-go-live review | Findings, corrective actions, and audit logs |
| Reassessment or retirement | Change assessment and renewal or retirement plan | Named AI owner | Renewal, change, or retirement approval | Risk assessment, decision, and decommissioning evidence |
For ePHI systems, retained records must document how risks to confidentiality, integrity, and availability were assessed and reduced under the HIPAA Security Rule.[15][16]
Start with one defined workflow, location, user group, and patient population. Before launch, set the pilot period, baseline measures, acceptance thresholds, and review dates. Expand only when clinical and operational owners show that controls and monitoring will remain effective at the proposed scale. Expansion requires a new approval decision, not a routine extension of the pilot.[1][3][17] Apply that discipline to keep clinical AI safe, open to review, and limited to its approved workflow.
FAQs
How can we reduce AI review burden without weakening safety?
Match oversight to clinical impact with risk-based triage. Reserve intensive, multidisciplinary reviews for high-impact clinical decision support. Use a simpler review process for lower-risk administrative tools.
Keep intake and the tool inventory in one place, give each tool an accountable owner, and automate routing and audit trails. Track performance indicators, such as override rates and drift, continuously. Use those signals to trigger reviews when needed instead of relying on infrequent manual audits.
What if a vendor withholds AI validation data?
Block go-live if the vendor withholds key AI validation data. During procurement and due diligence, require model cards, bias testing summaries, performance validation studies, and details on training-data composition.
Contracts must grant audit rights for AI-specific records, including data lineage and training logs. If the vendor refuses to provide this evidence, use your contractual rights to suspend or terminate the relationship to protect patient safety and uphold compliance standards.
How do we resolve conflicting clinical and privacy approvals?
A formal AI Governance Committee charter should spell out when to escalate an issue and who has authority to resolve it. Use a structured benefit-risk framework that puts patient safety first. Cybersecurity or privacy risks that remain unmitigated and threaten patient safety must block approval, regardless of clinical benefit [1].
For conflicts that aren’t safety-critical, document risk acceptance, put compensating controls in place, and set a timeline for remediation. If disagreements persist, the CISO, CMO/CMIO, and Privacy Officer can escalate them to executive leadership [1].
